PETVIVO ANIMAL HEALTH, INC. RELEASES CONFERENCE AND EXHIBIT SCHEDULE FOR 2026-2027

MINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc. ("PetVivo"), in cooperation with its parent, PetVivo Holdings, Inc. (OTCQX: PETV), and its other subsidiaries, Somatrix Technologies, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for equine and companion animals today announced its veterinary conference and exhibition schedule for the remainder of 2026 and through April 2027.

The conference schedule is designed to provide PetVivo with continued opportunities to engage directly with veterinarians, specialists, practice owners and other animal health professionals; increase awareness of Spryng® with OsteoCushion® Technology; provide clinical and product education; and strengthen relationships with veterinary practices across the companion animal and equine markets.

The schedule includes several of the veterinary profession’s leading educational and industry events. PetVivo will begin this week at the Southwest Veterinary Symposium (“SWVS”) in San Antonio, where the Company will exhibit and sponsor a canine joint-injection wet lab. SWVS features more than 400 hours of RACE-approved continuing education and more than 250 exhibitors, providing PetVivo an opportunity to engage veterinarians through both clinical education and direct interaction.

PetVivo also plans to participate in an event hosted by Veterinary Growth Partners (“VGP”), whose network includes more than 7,000 independent veterinary hospitals. The VGP relationship provides PetVivo with an opportunity to engage with independent veterinary practices and practice leaders who represent an important segment of the companion animal health market.

The schedule further includes the American College of Veterinary Surgeons (“ACVS”) Surgery Summit, which brings together veterinary surgeons and other professionals focused on advanced patient care; and the American Association of Equine Practitioners (“AAEP”) Annual Convention, the world’s largest meeting of equine veterinarians. AAEP’s community includes more than 9,000 veterinarians and veterinary students, making the convention an important opportunity for PetVivo to expand awareness of Spryng within the equine veterinary community.

In early 2027, PetVivo plans to participate in VMX 2027 in Orlando and WVC Vegas 2027, two of the veterinary profession’s major educational and industry gatherings. PetVivo will also participate in the International Veterinary Academy of Pain Management (“IVAPM”) Pain Management Forum in Minneapolis, an event specifically focused on advancing the prevention, detection and management of pain in animals.

“We are entering a very active period of direct engagement with the veterinary community, beginning this week at SWVS and continuing through some of the profession’s most important meetings,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Our goal is to put Spryng and the clinical information supporting its use directly in front of veterinarians and other veterinary professionals who manage joint-related conditions and lameness every day. Whether we are meeting independent veterinary practices through VGP, veterinary surgeons at ACVS, equine practitioners at AAEP or the broader veterinary community at VMX and WVC, these events provide valuable opportunities to educate clinicians, listen to their needs, strengthen relationships with existing customers and introduce Spryng to new veterinary practices. We believe consistent clinical education and direct veterinarian engagement are important components of our strategy to expand awareness and adoption of Spryng.”

Spryng^® with OsteoCushion^® Technology is PetVivo’s lead commercial product and is a veterinarian-administered, intra-articular veterinary medical device for the management of lameness and other joint-related afflictions, including osteoarthritis, in companion animals and horses.

PetVivo’s currently scheduled 2026–2027 conferences and exhibitions include:

The conference schedule reflects PetVivo’s continued commitment to veterinary education and to increasing direct engagement with the veterinarians and practice leaders responsible for advancing animal health and patient care.

For more information about PetVivo Holdings, Inc. and its innovative products please contact info1@petvivo.com or visit https://petvivo.com/, https://www.petvivoanimalhealth.com/ and https://www.sprynghealth.com.

About PetVivo Holdings, Inc.

PetVivo Holdings, Inc. (OTCQX: PETV), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., is an emerging biomedical device company focused on the development, manufacturing, commercialization and licensing of innovative medical devices, biomaterials and therapeutics for animal and human health. The Company's strategy is to leverage its proprietary technologies, intellectual property and scientific expertise to develop and commercialize products addressing unmet needs across veterinary and human medicine.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead product, SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Forward-Looking Statements

The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.